Osteosarcoma Pathogenesis Leads the Way to New Target Treatments

Isabel Fernandes; Cecília Melo-Alvim; Raquel Lopes-Brás; Miguel Esperança-Martins; Luís Costa

doi:10.3390/ijms22020813

Osteosarcoma Pathogenesis Leads the Way to New Target Treatments

Int J Mol Sci. 2021 Jan 15;22(2):813. doi: 10.3390/ijms22020813.

Authors

Isabel Fernandes^{1

2}, Cecília Melo-Alvim¹, Raquel Lopes-Brás¹, Miguel Esperança-Martins^{1

2

3}, Luís Costa^{1

2}

Affiliations

¹ Medical Oncology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1600 Lisbon, Portugal.
² Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 1600 Lisbon, Portugal.
³ Sérgio Dias Lab, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 1600 Lisbon, Portugal.

Abstract

Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.

Keywords: molecular targets; osteosarcoma; pathogenesis.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Bone Neoplasms / drug therapy*
Bone Neoplasms / metabolism
Humans
Molecular Targeted Therapy / methods*
Osteosarcoma / drug therapy*
Osteosarcoma / metabolism
Prognosis
Receptor, ErbB-2 / antagonists & inhibitors
Receptor, ErbB-2 / metabolism
Receptor, IGF Type 1 / antagonists & inhibitors*
Receptor, IGF Type 1 / metabolism
Trastuzumab / therapeutic use

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Receptor, ErbB-2
Receptor, IGF Type 1
Trastuzumab
figitumumab